Open Access

ARTICLE

No predictive value of serum interleukin-6 and transforming growth factor-β1 in identifying patients with a first restenosis, recurrent restenosis or a history of restenosis

Bartosz Hudzik¹, Janusz Szkodzinski¹, Wojciech Romanowski², Krzysztof Wilczek¹, Rafal Wojnar¹, Andrzej Lekston¹, Lech Polonski¹, Barbara Zubelewicz-Szkodzinska²

1 3^rd Department of Cardiology, Silesian Center for Heart Disease, Silesian Medical University, Zabrze, Poland 2 Department of Internal Diseases, Silesian Medical University, Bytom, Poland

* Corresponding Author: B. Hudzik,

European Cytokine Network 2009, 20(3), 135-139. https://doi.org/10.1684/ecn.2009.0160

Accepted 26 July 2009;

Abstract

Background. The efficacy of percutaneous coronary intervention (PCI) is limited by the need for repeat revascularization resulting from restenosis. The restenosis rate after treatment for in-stent restenosis (recurrent restenosis) is high (> 30%). Numerous studies have suggested the predictive value of interleukin 6 (IL-6) and transforming growth factor β1 (TGF-β1). Methods. We sought to determine whether serum levels of IL-6 and TGF-β1 could help identify individuals with recurrent restenosis. Thirty seven patients with a history of stent implantation were enrolled and divided into three groups: (1) patients with a current, first restenosis (n = 9); (2) patients with current restenosis and at least one prior restenosis (recurrent restenosis) (n = 11), and (3) patients with a history of restenosis, but without current restenosis (n = 17). Results. The baseline profile was similar in all three groups. The median (25^th -75^th percentile) concentrations of IL-6 were: group 1 – 2.8 (1.4-5.5); group 2 – 2.6 (0.6-8.6); group 3 – 2.4 (0.9-4.7) p = 0.69 and TGF-β1: group 1 – 3.6 (0.2-14.4); group 2 – 4.2 (1.8-57.6); group 3 – 6.6 (2.8-30.0) p = 0.57. Moreover we found no correlation, either between diameter stenosis and IL-6 (R = 0.10; p = 0.38) or TGF-β1 (R = 0.10; p = 0.57). Both IL-6 (AUC 0.59 p = 0.4 and AUC 0.51 p = 0.9) and TGF-β1 (AUC 0.64 p = 0.2 and AUC 0.50 p = 0.9) failed to provide significant results in receiver-operating characteristic analysis. Conclusion. We report that there is no association between the severity of diameter stenosis (restenosis) and IL-6 or TGF-β1 concentrations. Our findings might suggest that levels of IL-6 and TGF-β1 have no predictive value for identifying patients with recurrent restenosis.

---

Keywords

---